Romidepsin in Peripheral and Cutaneous T-Cell Lymphoma: Mechanistic Implications from Clinical and Correlative Data

Romidepsin is an epigenetic agent approved for the treatment of patients with cutaneous or peripheral T-cell lymphoma (CTCL and PTCL). Here we report data in all patients treated on the National Cancer Institute 1312 trial, demonstrating long-term disease control and the ability to retreat patients...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Br J Haematol
Main Authors: Bates, Susan E., Eisch, Robin, Ling, Alex, Rosing, Douglas, Turner, Maria, Pittaluga, Stefania, Prince, H. Miles, Kirschbaum, Mark H., Allen, Steven L., Zain, Jasmine, Geskin, Larisa J., Joske, David, Popplewell, Leslie, Cowen, Edward W., Jaffe, Elaine S., Nichols, Jean, Kennedy, Sally, Steinberg, Seth M., Liewehr, David J., Showe, Louise C., Steakley, Caryn, Wright, John, Fojo, Tito, Litman, Thomas, Piekarz, Richard L.
Format: Artigo
Jezik:Inglês
Izdano: 2015
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4675455/
https://ncbi.nlm.nih.gov/pubmed/25891346
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.13400
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki